Abstract
The antibacterial chemotherapeutic era, which has dominated much of medicine in the past 50 years, was really initiated by the introduction of the sulfonamides in 1932 (see Domagk 1935). After widespread and effective use of sulfonamides in a variety of infectious diseases, resistant organisms began to emerge, at first slowly, but then with frightening rapidity. In Japan, for example, species of Shigella were invariably sensitive to sulfonamides in the mid 1940 s, but by early 1952 were just as invariably resistant. Fortunately, or so it was naively thought at the time, newer drugs were introduced to which the organisms were susceptible, including tetracycline, chloramphenicol, and streptomycin, and therapy once again became possible. However, over the next 5 years there emerged organisms resistant to each of these agents, and of greater importance, to several of them at the same time. By 1957 it was observed that an initially sulfonamide-resistant but otherwise sensitive isolate in a patient treated with just one of the agents, would suddenly appear with the resistance pattern of sulfonamide, streptomycin, tetracycline, and chloramphenicol. Akiba et al. (1960) and Ochiai et al. (1959) independently suggested that the information mediating such one-step resistance might be transferred from bacteria to bacteria, and proceeded to demonstrate this in vitro. In this fashion the world of transferable drug resistance (R factors) and the biology of extrachromosomal deoxyribonucleic acid, plasmids, was opened to the eyes and the minds of scientists. The past two decades of the chemotherapeutic era have been dominated as much by transferable drug resistance as by the introduction of new and potent drugs or combinations such as trimethoprim/sulfamethoxazole (TMP/SMX, Cotrimoxazole, Bactrim, Septrin, Septra). In this chapter, we will present an overview of TMP/SMX as a guide to the detailed information to follow and as a perspective for clinical thinking in current and future use of the drug or its individual components.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Akiba T, Koyama K, Ishiki Y, Kimura S, Fukushima J (1960) On the mechanism of development of multiple drug-resistant clones of Shigella. Jpn J Microbiol 4: 219–227
Amyes SGB, Smith JT (1975) R-factor conferred ability to mutate to trimethoprim resistance. J Pharm Pharmacol [Suppl 2] 27: 44 P
Amyes SGB, Smith JT (1978) R-factor mediated dihydrofolate reductases which confer trimethoprim resistance. J Gen Microbiol 107: 263–271
Blackwell EA, Hauson CAT, Leer J, Bain B (1978) Acute pancytopenia due to megaloblastic arrest in association with cotrimoxazole. Med J Aust 2: 38–41
Brumfitt W, Hamilton-Miller JMT (1979) General survey of trimethoprim combination in the treatment of urinary tract infections. Infection [Suppl 4] 7: 388–393
Bushby SRM (1973) Trimethoprim sulfamethoxazole: in vitro microbiological aspects. J Infect Dis [Suppl] 128: 442–462
Cattell WR, McSherry MA, Brooks HL, O’Grady FW (1976) The carriage of Escherichia colion the periurethral area and in the feces in patients on long-term low dose cotrimoxazole therapy. Clin Nephrol 6: 506–508
Chattopadhyay B (1972) Trimethoprim-sulfamethoxazole in urinary tract infection due to Streptococcus faecalis. J Clin Pathol 25: 531–533
Datta N, Hedges RW (1972) Trimethoprim resistance conferred by W plasmids in Enterobactcriaccae. J Gen Microbiol 72: 349–355
Domagk G (1935) Ein Beitrag zur Chemotherapie der bakteriellen Infektionen. Dt Med Wochenschr 61: 250–253
Grey D, Hamilton-Miller JMT, Brumfitt W (1979) Incidence and mechanisms of resistance to trimethoprim in clinically isolated gram-negative bacteria. Chemotherapy 25: 147–156
Grose WE, Bodey GP (1980) Intravenous trimethoprim-sulfamethoxazole alone or com- bined with tobramycin for infections in cancer patients. Am J Med Sci 279: 4–13
Grünberg E, Prince HN, DeLorenzo WF (1970) The in vivo effect of folinic acid (citrovorum factor) on the potentiation of the antibacterial activity of sulfisoxasole by trimethoprim. J Clin Pharmacol 10: 231–234
Grüneberg RN, Smellie JM, Leakey A, Atkin WS (1976) Long-term, low dose cotrimoxazole in prophylaxis of childhood urinary tract infection. Bacteriological aspects. Br Med J 2: 206–208
Grüneberg RN, Bendall MJ (1979) Hospital outbreak of trimethoprim resistance in pathogenic coliform bacteria. Br Med J 2: 7–9
Gurwith MJ, Brunton JL, Lank BA, Harding GKM, Ronald AR (1979) A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 66: 248–256
Hitchings GH (1973) Biochemical background of trimethoprim-sulfamethoxazole. Med J Aust [Suppl] 1: 5–9
Kahn SB, Fein SA, Brodsky I (1968) Effect of trimethoprim on folate metabolism in man. Clin Pharmacol Ther 9: 550–560
Knothe H (1973) The effect of a combined preparation of trimethoprim and sulphamethoxazole following short-term and long-term administration on the flora of the human gut. Chemotherapy 18: 284–296
Lacey RW, Lord VL, Gunasekera HKW, Lieberman PJ, Luxton DEA (1980) Comparison of trimethoprim alone with trimethoprim-sulphamethoxazole in the treatment of respiratory and urinary infections with particular reference to selection of trimethoprim resistance. Lancet 1: 1270–1273
Naff H (1971) On the changes in the intestinal flora induced in man by Bactrim. Pathol Microbiol 37: 1–22
Ochiai K, Yamanaka T, Kimura K, Sowada O (1959) Inheritance of drug resistance (and its transfer) between Shigellastrains and between Shigellaand E. colistrains. Nihon Iji Shimpo 1861: 34
Pattishall KH, Acar J, Burchall JJ, Goldstein FW, Harvey RJ (1977) Two distinct types of trimethoprim-resistant dihydrofolate reductase specified by R-plasmids of different compatibility groups. J Biol Chem 252: 2319–2323
Richards H, Datta N, Sojka WJ, Wray C (1978) Trimethoprim-resistant plasmids and transposons in salmonella. Lancet 2: 1194–1195
Schimpff SC (1980) Infection prevention during profound granulocytopenia. New ap- proaches to alimentary canal microbial suppression. Ann Intern Med 93: 358–361
Stamey TA, Condy M, Mihara G (1977) Prophylactic efficacy of nitrofurantoin macrocrystals and trimethoprim-sulfamethoxazole in urinary infections: biologic effects on the vaginal and rectal flora. N Engl J Med 296: 780–783
Stone D, Smith SL (1979) The amino acid sequence of the trimethoprim-resistant dihydrofolate reductase specified in Escherichia coliby R plasmid R 67. J Biol Chem 254: 10857–10861
Tennhammer-Ekman B, Sköld O (1979) Trimethoprim-resistance plasmids of different or- igin encode different drug-resistant dihydrofolate reductases. Plasmid 2: 334–346
Towner KJ, Pearson NJ, Cattell WR, O’Gray F (1979) Trimethoprim R plasmids isolated during long-term treatment of urinary tract infections with cotrimoxazole. J Antimicrob Agents 5: 45–52
Towner KJ, Pearson NJ, Pinn PA, O’Grady F (1980) Increasing importance of plasmid-mediated trimethoprim resistance in enterobacteria: two six-month clinical surveys. Br Med J 280: 517–519
West B, White G (1979) A survey of trimethoprim resistance in the enteric bacterial flora of farm animals. J Hyg (Lond) 82: 481–488
Wormser GP, Keusch GT (1979) Trimethoprim-sulfamethoxazole in the United States. Ann Intern Med 91: 420–429
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wormser, G.P., Keusch, G.T. (1983). Trimethoprim/Sulfamethoxazole: An Overview. In: Hitchings, G.H. (eds) Inhibition of Folate Metabolism in Chemotherapy. Handbook of Experimental Pharmacology, vol 64. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81890-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-81890-5_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81892-9
Online ISBN: 978-3-642-81890-5
eBook Packages: Springer Book Archive